Metabolic syndrome: A multifaceted risk factor for kidney stones

References

• Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004;109:433–8.
   PubMed Web of Science ®Google Scholar
• Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002;288:2709–16.
   PubMed Web of Science ®Google Scholar
• Hari P, Nerusu K, Veeranna V, Sudhakar R, Zalawadiya S, Ramesh K, et al. A gender-stratified comparative analysis of various definitions of metabolic syndrome and cardiovascular risk in a multiethnic US population. Metab Syndr Relat Disord 2012;10:47–55.
   Google Scholar
• Wang J, Ruotsalainen S, Moilanen L, Lepisto P, Laakso M, Kuusisto J. The metabolic syndrome predicts cardiovascular mortality: a 13-year follow-up study in elderly non-diabetic Finns. Eur Heart J 2007;28:857–64.
   PubMed Web of Science ®Google Scholar
• West B, Luke A, Durazo-Arvizu RA, Cao G, Shoham D, Kramer H. Metabolic syndrome and self-reported history of kidney stones: the National Health and Nutrition Examination Survey (NHANES III) 1988–1994. Am J Kidney Dis 2008;51:741–7.
   PubMed Web of Science ®Google Scholar
• Domingos F, Serra A. Nephrolithiasis is associated with an increased prevalence of cardiovascular disease. Nephrol Dial Transplant 2011;26:864–8.
   PubMed Web of Science ®Google Scholar
• Tiselius HG. Urinary tract stone disease: are all problems solved? Scand J Urol 2013;47:4–9.
   PubMed Web of Science ®Google Scholar
• Vague J. The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease. Am J Clin Nutr 1956;4:20–34.
   PubMed Web of Science ®Google Scholar
• Siener R, Glatz S, Nicolay C, Hesse A. The role of overweight and obesity in calcium oxalate stone formation. Obes Res 2004;12:106–13.
   PubMedGoogle Scholar
• Cupisti A, Meola M, D’Alessandro C, Bernabini G, Pasquali E, Carpi A, et al. Insulin resistance and low urinary citrate excretion in calcium stone formers. Biomed Pharmacother 2007;61:86–90.
   PubMed Web of Science ®Google Scholar
• Ando R, Suzuki S, Nagaya T, Yamada T, Okada A, Yasui T, et al. Impact of insulin resistance, insulin and adiponectin on kidney stones in the Japanese population. Int J Urol 2011;18:131–8.
   Google Scholar
• Weinberg AE, Patel CJ, Chertow GM, Leppert JT. Diabetic severity and risk of kidney stone disease. Eur Urol 2014;65:242–7.
   Google Scholar
• Strohmaier WL, Wrobel BM, Schubert G. Overweight, insulin resistance and blood pressure (parameters of the metabolic syndrome) in uric acid urolithiasis. Urol Res 2012;40:171–5.
   PubMedGoogle Scholar
• Kadlec AO, Greco K, Fridirici ZC, Hart ST, Vellos T, Turk TM. Metabolic syndrome and urinary stone composition: what factors matter most? Urology 2012;80:805–10.
   PubMed Web of Science ®Google Scholar
• Abate N, Chandalia M, Cabo-Chan AV Jr, Moe OW, Sakhaee K. The metabolic syndrome and uric acid nephrolithiasis: novel features of renal manifestation of insulin resistance. Kidney Int 2004;65:386–92.
   PubMed Web of Science ®Google Scholar
• Bobulescu IA. Renal lipid metabolism and lipotoxicity. Curr Opin Nephrol Hypertens 2010;19:393–402.
   PubMed Web of Science ®Google Scholar
• Fuster DG, Bobulescu IA, Zhang J, Wade J, Moe OW. Characterization of the regulation of renal Na+/H+ exchanger NHE3 by insulin. Am J Physiol Renal Physiol 2007;292:F577–85.
   PubMed Web of Science ®Google Scholar
• Kohjimoto Y, Sasaki Y, Iguchi M, Matsumura N, Inagaki T, Hara I. Association of metabolic syndrome traits and severity of kidney stones: results from a nationwide survey on urolithiasis in Japan. Am J Kidney Dis 2013;61:923–9.
   PubMed Web of Science ®Google Scholar
• Borghi L, Meschi T, Guerra A, Briganti A, Schianchi T, Allegri F, et al. Essential arterial hypertension and stone disease. Kidney Int 1999;55:2397–406.
   PubMed Web of Science ®Google Scholar
• Taylor EN, Mount DB, Forman JP, Curhan GC. Association of prevalent hypertension with 24-hour urinary excretion of calcium, citrate, and other factors. Am J Kidney Dis 2006;47:780–9.
   PubMedGoogle Scholar
• Coe FL, Evan AP, Worcester EM, Lingeman JE. Three pathways for human kidney stone formation. Urol Res 2010;38:147–60.
   PubMedGoogle Scholar
• Schepers MS, van Ballegooijen ES, Bangma CH, Verkoelen CF. Crystals cause acute necrotic cell death in renal proximal tubule cells, but not in collecting tubule cells. Kidney Int 2005;68:1543–53.
   PubMed Web of Science ®Google Scholar
• Khan SR, Rodriguez DE, Gower LB, Monga M. Association of Randall plaque with collagen fibers and membrane vesicles. J Urol 2012;187:1094–100.
   Google Scholar
• Low RK, Stoller ML, Schreiber CK. Metabolic and urinary risk factors associated with Randall's papillary plaques. J Endourol 2000;14:507–10.
   Google Scholar
• Sakhaee K. Recent advances in the pathophysiology of nephrolithiasis. Kidney Int 2009;75:585–95.
   PubMedGoogle Scholar
• Stapleton PA, James ME, Goodwill AG, Frisbee JC. Obesity and vascular dysfunction. Pathophysiology 2008;15:79–89.
   PubMedGoogle Scholar
• Li G, Barrett EJ, Barrett MO, Cao W, Liu Z. Tumor necrosis factor-alpha induces insulin resistance in endothelial cells via a p38 mitogen-activated protein kinase-dependent pathway. Endocrinology 2007;148:3356–63.
   PubMed Web of Science ®Google Scholar
• Holoch PA, Tracy CR. Antioxidants and self-reported history of kidney stones: the National Health and Nutrition Examination Survey. J Endourol 2011;25:1903–8.
   PubMed Web of Science ®Google Scholar
• Canales BK, Anderson L, Higgins L, Ensrud-Bowlin K, Roberts KP, Wu B, et al. Proteome of human calcium kidney stones. Urology 2010;76:1017.e13–20.
   Google Scholar
• Byer K, Khan SR. Citrate provides protection against oxalate and calcium oxalate crystal induced oxidative damage to renal epithelium. J Urol 2005;173:640–6.
   PubMed Web of Science ®Google Scholar
• Umekawa T, Hatanaka Y, Kurita T, Khan SR. Effect of angiotensin II receptor blockage on osteopontin expression and calcium oxalate crystal deposition in rat kidneys. J Am Soc Nephrol 2004;15:635–44.
   PubMed Web of Science ®Google Scholar
• Taguchi K, Okada A, Yasui T, Kobayashi T, Ando R, Tozawa K, et al. Pioglitazone, a peroxisome proliferator activated receptor gamma agonist, decreases renal crystal deposition, oxidative stress and inflammation in hyperoxaluric rats. J Urol 2012;188:1002–11.
   PubMed Web of Science ®Google Scholar